Onco Wiki / Biomarker

HBV-DNA quantitativ — virale Belastungsüberwachung während der Nukleos(t)id-Analogtherapie

Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.

IDBIO-HBV-DNA-QUANTITATIVE-MONITORING
ArtBiomarker
Aliase
HBV DNA quantitative ÜberwachungHBV DNA serielleHBV PCR quantitativÜberwachung der Viruslast der HBVHBV ДНК кількісна — моніторинг вірусного навантаження під час нуклеоз(т)идної терапії
Statusreviewed 2026-05-18 | pending_clinical_signoff
ErkrankungenDIS-HCC
QuellenSRC-AASLD-HBV-2024 SRC-AASLD-HCC-2023 SRC-EASL-HBV-2025

Biomarker-Fakten

Biomarker-Typviral_load
Messung
VerfahrenReal-time quantitative PCR (HBV DNA, IU/mL); high-sensitivity assay (LOD ≤10-20 IU/mL) required
EinheitenIU/mL
Typischer Bereich
  • 0
  • 100000000
Verwandte BiomarkerBIO-HBV-STATUS

Anmerkungen

Quantitative HBV DNA used to TRACK viral suppression over time during chronic-HBV antiviral therapy (entecavir or tenofovir TDF/TAF — first- line nucleos(t)ide analogues per AASLD 2024 / EASL 2025). Distinct from BIO-HBV-STATUS (serology-based screening / treatment-decision gate). Two clinical contexts: (1) Treatment monitoring in HBeAg+/HBeAg− chronic HBV: baseline HBV DNA + ALT + HBeAg + HBsAg → start NA → recheck q3 months for first year, then q6 months. Goal: HBV DNA undetectable on treatment; ALT normalization; HBeAg seroconversion (HBeAg+ patients) or HBsAg loss (functional cure — rare on NA monotherapy, ~1% per year). Virologic breakthrough (≥1-log rise from nadir) prompts adherence review then switch (entecavir → tenofovir if NA-naïve resistance). (2) Prophylaxis monitoring during B-cell-depleting therapy (rituximab, obinutuzumab) or anti-CD38 (daratumumab, isatuximab) in HBsAg+ or anti-HBc+ patients: entecavir prophylaxis baseline → HBV DNA q3 months during chemotherapy and for 12+ months post-treatment; any detectable HBV DNA = reactivation, hepatology consult. HCC surveillance in chronic HBV (cirrhotic OR Asian male >40 OR Asian female >50 OR African >20 OR family histo...

Verwendet von

Therapeutische Relevanz